newsfilter
← Latest News
GlobeNewswire·

Turning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational Updates

On Track for TRIDENT-1 ROS1+ NSCLC Topline Data Disclosure and Pre-NDA Meeting Anticipated 2Q 2022 Eighth Regulatory Designation Granted for Repotrectinib with Breakthrough Therapy Designation in China Other Clinical and Preclinical Programs Continue